EGFR and cancer: Epidermal growth factor receptor blockade by monoclonal antibodies or small molecule TK inhibitors (TKIs), such as gefitinib or erlotinib, has now entered clinical practice in patients affected by different types of cancer (Mendelsohn and Baselga, 2006; Ciardiello and Tortora, 2008).